TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Telintra for Treatment of Chemotherapy Induced Neutropenia in Patients With Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed NSCLC~* Stage IIIb-Stage IV NSCLC~* ECOG performance status of 0-2~* Adequate liver and renal function~* Adequate bone marrow reserve~Exclusion Criteria:~* Treatment with neoadjuvant or adjuvant chemotherapy within 1 year~* Histologically confirmed mixed tumors containing small cell elements~* Treatment with radiotherapy (except limited in nature) within 3 weeks of randomization~* History of bone marrow transplantation or stem cell support~* Known history of CNS metastasis unless the patient has had treatment with surgery or radiotherapy, is neurologically stable and does not require oral or IV steroids or anticonvulsants~* History of HIV~* Grade 3 or 4 peripheral neuropathy~* Weightloss greater than 5% within 6 months~* Uncontrolled pleural effusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ezatiostat hydrochloride (Telintra®) (Type: EXPERIMENTAL): Chemotherapy with docetaxel and carboplatin followed by Telintra until ANC recovery
- No Intervention (Type: NO_INTERVENTION): Chemotherapy with docetaxel and carboplatin alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Does Percutaneous Tibial Nerve Stimulation (PTNS) Improve Outcomes in Patients Presenting With Fecal Incontinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* Able to provide informed consent~* Has severe fecal incontinence (defined as weekly episodes of incontinence of mucus, liquid or solid stool)~* Available to present for weekly treatments~* Available for follow-up at 3, 6, and 12 months~Exclusion Criteria:~1. Severe cardiopulmonary disease~2. Lesion of the Tibial Nerve~3. Use of a cardiac pacemaker or implantable defibrillator~4. History of inflammatory bowel disease~5. Active anal fissure, fistula, or abscess~6. Active rectal bleeding which has not been evaluated with appropriate testing, such as colonoscopy~7. Has a sphincter injury that needs sphincteroplasty~8. Wants to pursue aggressive surgical therapy with a colostomy or an artificial bowel sphincter~9. Severe distal venous insufficiency~10. Uncontrolled diabetes with peripheral nerve involvement~11. Immunosuppression~12. Pregnant or planning on becoming pregnant during treatment~13. Patients prone to bleeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- No active treatment (Type: SHAM_COMPARATOR): None
- stimulation/treatment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Autonomic Disorders: A Training Protocol

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA - PATIENTS:~Patients may be included if they are at least 18 years old and are known or suspected to have failure of one or more components of the autonomic nervous system, small fiber neuropathy, inherited dysautonomia, orthostatic intolerance, neurocardiogenic syncope, status post endoscopic thoracic sympathectomy, or disorders of catecholamine synthesis or fate.~Children greater than two years old may be enrolled in this Protocol if they might personally benefit from the tests in the Protocol through the establishment of a diagnosis.~EXCLUSION CRITERIA - PATIENTS:~There are no exclusion criteria for the study as a whole.~INCLUSION CRITERIA - HEALTHY VOLUNTEERS:~Healthy adult Volunteers (at least 18 years old) may be included, pending normal or medically insignificant results of history and physical examination. A repeat history and physical examination is required if more than 6 months have gone by from a previous workup.~EXCLUSION CRITERIA - HEALTHY VOLUNTEERS:~A candidate Healthy Volunteer will be excluded if the person has any of the following: symptoms of autonomic dysfunction, including lightheadedness, fainting, abnormalities of sweating, frequent nausea, vomiting, constipation, or diarrhea, or urinary frequency or retention. If the Volunteer has a condition requiring medication that in the judgment of the Investigators will affect results of the pupillometric tests under this Protocol, the Volunteer may be included for training purposes.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Healthy Volunteers (Type: None): Volunteers will be studied for Fellows to practice and gain normative values for pupillometric function.
- Patients (Type: None): Referred patients with known or suspected abnormalities of one or more components of the autonomic nervous system

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Comparison of Patellofemoral Pain Syndrome Outcomes After Blood Flow Restriction Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Diagnosis of patellofemoral pain syndrome (PFPS) or non-specific anterior knee pain (NSAKP) and plan to attend Gaylord Specialty Healthcare Physical Therapy~Exclusion Criteria:~Member of a defined vulnerable population, women who are or suspected to be pregnant, prisoners, children under 15, or other protected populations~Body mass of the leg preventing the cuff from fitting properly~Radiographic evidence of osteoarthritis (≥ Kellgren-Lawrence Grade 2)~History of intra-articular injection into either knee within 3 -months~Uncontrolled or untreated inflammatory disorder~Acute inflammatory disorder~Uncontrolled Diabetes and/or peripheral neuropathy, impaired circulation~Uncontrolled cardiac conditions including uncontrolled hypertension~Areas of thrombophlebitis, thrombosis~Distal wounds or pain below the knee \>4/10~History of or current rhabdomyolysis~Prolonged immobilization (\>3 months)~Sickle cell anemia~Lymphadenectomy~Varicose veins, or a history of personal or immediate family history (parental or sibling) of deep vein thrombosis~Current infection at or below the level of cuff placement~Malignancies in or below the area to be treated~Other conditions/medications that would interfere with subject safety or data collection in the opinion of the PI~Subjects with an increased risk of non-response as determined by the therapist~Once entered in the study, a diagnosis change that affects participation

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Blood flow restriction and standard of care therapy (Type: EXPERIMENTAL): The experimental BFR therapy will be incorporated into the standard therapy sessions and will not elongate the treatment session, quantity of sessions or incur any additional cost. As the participant progresses over time in therapy sessions, the discretion of the PT will determine when they have graduated beyond receiving any benefit from BFRT as demonstrated by quad strength.
- Sham and standard of care therapy (Type: PLACEBO_COMPARATOR): The sham comparator control group will also follow the Exercise Protocol in their physical therapy sessions with a non inflated blood flow restriction cuff attached in the same position as the experimental group. Similar to the intervention group, as participant's progress in therapy, the Physical Therapist will use their clinical decision making to advance the person through resistance and repetition increases.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cryoablation of Bone Metastases From Endocrine Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with bone metastases from thyroid, adrenal or neuroendocrine tumor diagnosis, associated to one of the following: pain; risk fracture; risk of compression of spinal cord; hypercalcemia; performance status (ECOG) 0-3; mean life expectancy over one month;~Exclusion Criteria:~* age \< 18 years~* active anticoagulant therapy or uncorrectable coagulopathy~* pregnancy or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cryoablation +- cementoplasty treated patients (Type: OTHER): cone beam computed tomography guided cryoablation +- cementoplasty

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Oral Iron Substitution for Orthopedic Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age over 55 years~* indication for patient blood management for elective orthopedic surgery~* listed for a orthopedic surgery (e.g. hip or knee replacement) 5-7 weeks after begin of patient blood management~* Haemoglobin male \< 12-13g/dl, female \<11-12g/dl~* written informed consent after written and verbal information~Exclusion Criteria:~* indication for treatment with erythropoietin~* pregnancy~* nursing period~* diarrhea or tendency to diarrhea~* fructose intolerance~* pre - menopause~* permanent or expected blood loss~* participation in other study~* expected compliance problems~* legal incapacity

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OLEOvital (Type: OTHER): 30mg iron are being administered orally twice a day for a period of 4 Weeks it is a granulated powder which is taken orally and then solved with saliva, without taking water

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects ages 6 to 21 who have loss of smell (anosmia) or dysosmia (disordered smell perception) and thought to have occurred due to COVID-19.~* Subjects who are able to complete the smell test (UPSIT), self-report their loss of smell, and do the assigned daily therapy.~Exclusion Criteria:~* Duration of anosmia or dysosmia \<60 days~* Previous smell retraining~* Prior interventions for loss of smell (excluding those on Flonase and Azelastine)~* Contraindications for nasal budesonide treatment, as determined by the treating physician~* Active cigarette smoker or use of vapes~* Previous head trauma~* Congenital anosmia~* History of brain tumor~* Neurocognitive disorders~* Multiple sclerosis~* Seizure disorder~* Cystic fibrosis~* Primary Ciliary Dyskinesia~* History of nasal polyps~* Inability to self-report

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Smell Retraining Only (Type: ACTIVE_COMPARATOR): Participants will undergo smell retraining for 8 weeks. Each week, participants will choose 4 scents. They will smell each item for 15 seconds very close to the nose once a day.
- Smell Retraining + Budesonide (Type: EXPERIMENTAL): Participants will undergo smell retraining as described above. They will also complete budesonide irrigations once a day by pouring 0.5mg/2ml of budesonide into a irrigation bottle with saline and irrigating the nose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Climacteric Therapy With Applied Relaxation Using InterNet

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A minimum of 7 moderate or severe hot flashes per 24 h or 50 hot flashes per week in average at least during one week before randomization (mild = hot flash without sweating as recognized by the woman but not disturbing the woman, moderate = hot flash and sweating as recognized by the woman but that does not lead to disruption of ongoing activity, severe = hot flash with sweating that leads to disruption of ongoing activity)~* Natural menopause (at least 12 months without any menstrual bleedings at all)~* At least 45 years of age during present year~* Access to computer with Internet~* Ability to read and speak Swedish~* Freely informed concent for participation~Exclusion Criteria:~* Induced menopause (e.g. hysterectomy, oophorectomy, chemotherapy, radiation therapy over abdominal- and/or pelvic region)~* Early or premature menopause (before 45 years of age)~* Breastcancer disease with ongoing therapy with antiestrogen or aromatase inhibitors~* Ongoing usage or use during the last month of hormone therapy or other treatment aimed for hot flashes (e.g. natural remedies affecting hot flashes, acupuncture, dietary supplements aimed to treat hot flashes~* Treatment with psychopharmacological drugs (e.g SSRI or SNRI) or frequent use of benzodiazepines, drugs for insomnia(\> 1 times/week)~* Untreated or unstable endocrinological- or metabolic disease( e.g thyroid disease)~* Undiagnosed vaginal bleeding after menopause

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Applied relaxation (Type: EXPERIMENTAL): Applied relaxation given by Internet during 10 weeks as a number of text-documents, audio-files and e-mail mediated support from therapists
- Waiting-list/control (Type: NO_INTERVENTION): No intervention for 10 weeks but the same registrations and diaries and forms as the interventional group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Intravenous Dalbavancin for Peritonitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients \> 18 years of age actively receiving peritoneal dialysis diagnosed with a gram + peritonitis determined to be a good candidate for dalbavancin treatment by the attending nephrology attending.~Exclusion Criteria:~Patients with contraindications to dalbavancin therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Sertraline Versus Cognitive Behaviour Therapy for Generalised Anxiety

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 or above~* Positive score of 10+ on GAD-7~* Primary diagnosis of GAD as diagnosed on MINI~* Failure to respond to NICE defined low intensity psychological interventions~Exclusion Criteria:~* Inability to complete questionnaires due to insufficient English or cognitive impairment;~* Current major depression~* Other comorbid anxiety disorder(s) of more severity or distress to the participant than their GAD;~* Significant dependence on alcohol or illicit drugs;~* Comorbid psychotic disorder, bipolar disorder;~* Treatment with antidepressants in past 8 weeks or any high intensity psychological therapy within past 6 months;~* Currently on contraindicated medication: monoamine oxidase Inhibitors within the past 14 days or pimozide;~* Patients with poorly controlled epilepsy;~* Known allergies to the Investigational Medicinal Product (IMP) or excipients;~* Concurrent enrolment in another Investigational Medicinal Product trial;~* Severe hepatic impairment;~* Women who are currently pregnant or planning pregnancy or lactating~* Patient on anti-coagulants~* History of bleeding disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sertraline (Type: ACTIVE_COMPARATOR): The pharmacological arm of the trial is the Selective Serotonin Reuptake Inhibitor (SSRI) Sertraline, prescribed at a daily dose of between 25 and 150mg by the patient's general practitioner (GP). If the medication is well tolerated and associated with reported clinical improvement we are asking the patients in this arm to continue taking it for 12 months.
- Cognitive Behavioural Therapy (CBT) (Type: ACTIVE_COMPARATOR): The psychological therapy arm of the trial is Cognitive Behavioural Therapy (CBT) delivered by high intensity psychological therapists from local IAPT services. They will provide 14 to 16 sessions of a manualised treatment developed specifically for use in GAD and will be trained in its delivery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Fusion Rate Using K2M VESUVIUS® Demineralized Fibers With K2M EVEREST® Spinal System

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of non-cervical spinal stenosis; spondylolisthesis (grade 1 or 2); and/or degenerative disc disease (DDD) with one or two contiguous levels requiring surgical intervention between L1-S1. Qualified patients will be confirmed for inclusion by patient history and radiographic studies~* Willing and able to comply with the requirements of the protocol including follow-up requirements~* Willing and able to sign a study specific informed consent~* Skeletally mature and I 18 years old at time of enrollment~Exclusion Criteria:~* Previous spine surgery at the index level~* Previous posterior spine surgery (e.g., posterior decompression) that destabilizes the lumbar spine~* Active systemic infection or infection at the operative site~* Co-morbid medical conditions of the spine or upper/lower extremities that may affect the lumbar spine neurological and/or pain assessment~* Metabolic bone disease such as osteoporosis and osteopenia that contradicts spinal surgery~* History of an osteoporotic fracture~* History of an endocrine or metabolic disorder (e.g., Paget's disease) known to affect bone and mineral metabolism~* Taking medications that may interfere with bony/soft tissue healing including chronic steroid use~* Known allergy to titanium or cobalt chrome~* Rheumatoid arthritis or other autoimmune disease or a systemic disorder such as HIV, active hepatitis B or C, or fibromyalgia~* Insulin-dependent type 1 or type 2 diabetes~* Medical condition (e.g., unstable cardiac disease, cancer) that may result in patient death or have an effect on outcomes prior to study completion~* Pregnant, or intends to become pregnant, during the course of the study~* Severe obesity (Body Mass Index \> 40)~* Physical or mental condition (e.g., psychiatric disorder, senile dementia, Alzheimer's disease, alcohol or drug addiction) that would interfere with patient self-assessment of function, pain, or quality of life.~* Involved in current or pending spinal litigation where permanent disability benefits are being sought~* Incarcerated at the time of study enrollment~* Current participation in an investigational study that may impact study outcomes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Explorative Study of Treatment of Contact Dermatitis Due to DiabetesDevices

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent, and for patients under the legal age consent by a legal guardian~* Clinically confirmed, active and evaluable irritant contact dermatitis (ICD)~* Age 6-20 at the time of signing the informed consent form (ICF)~* Ability to answer study questionnaires~Exclusion Criteria:~* Any type of skin irritation other than ICD~* Use of occlusive therapy for the treatment of their ICD, or unwilling to refrain from this treatment for duration of study~* For any other reason considered unsuitable by the investigator~* Pregnant or of child-bearing potential unwilling to use acceptable effective contraception

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Medical Device, an occlusive patch for 3 days.
- Control (Type: ACTIVE_COMPARATOR): Standard of Care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy